Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial

A. Decensi, C. Robertson, N. Rotmensz, G. Severi, P. Maisonneuve, V. Sacchini, P. Boyle, A. Costa, U. Veronesi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks and side-effects of either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects of their combination on cardiovascular risk factors within a prevention trial of tamoxifen. Baseline and 12-month measurements of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol, platelets and white blood cells were obtained in the following four groups: tamoxifen (n = 1117), placebo (n = 1112), tamoxifen and HRT (n = 68), placebo and HRT (n = 87). The analysis was further extended to women who were on HRT at randomization but discontinued it during the 12-month intervention period (n = 33 on tamoxifen and n = 35 on placebo) and to women who were not on HRT but started it during intervention (n = 36 in both arms of the study). Compared with small changes in the placebo group, tamoxifen was associated with changes in total, LDL- and HDL-cholesterol of approximately -9%, -19% and +0.2%, in continuous HRT users compared with -9%, -14% and -0.8% in never HRT users. Similarly, there was no interaction on platelet count. In contrast, the decrease in total and LDL-cholesterol levels induced by tamoxifen was blunted by two-thirds in women who started HRT while on tamoxifen (P = 0.051 for the interaction term). We conclude that the beneficial effects of tamoxifen on cardiovascular risk factors are unchanged in current HRT users, whereas they may be attenuated in women who start transdermal HRT while on tamoxifen. Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity.

Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalBritish Journal of Cancer
Volume78
Issue number5
Publication statusPublished - Sep 1998

Fingerprint

Hormone Replacement Therapy
Tamoxifen
Placebos
LDL Lipoproteins
HDL Cholesterol
Random Allocation
Platelet Count
LDL Cholesterol
Prescriptions
Leukocytes
Blood Platelets

Keywords

  • Breast neoplasm
  • Chemoprevention
  • Cholesterol
  • Oestrogen replacement therapy
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. / Decensi, A.; Robertson, C.; Rotmensz, N.; Severi, G.; Maisonneuve, P.; Sacchini, V.; Boyle, P.; Costa, A.; Veronesi, U.

In: British Journal of Cancer, Vol. 78, No. 5, 09.1998, p. 572-578.

Research output: Contribution to journalArticle

Decensi, A, Robertson, C, Rotmensz, N, Severi, G, Maisonneuve, P, Sacchini, V, Boyle, P, Costa, A & Veronesi, U 1998, 'Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial', British Journal of Cancer, vol. 78, no. 5, pp. 572-578.
Decensi, A. ; Robertson, C. ; Rotmensz, N. ; Severi, G. ; Maisonneuve, P. ; Sacchini, V. ; Boyle, P. ; Costa, A. ; Veronesi, U. / Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. In: British Journal of Cancer. 1998 ; Vol. 78, No. 5. pp. 572-578.
@article{e70fb64b22d245b7aec97ba95bfac6dd,
title = "Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial",
abstract = "The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks and side-effects of either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects of their combination on cardiovascular risk factors within a prevention trial of tamoxifen. Baseline and 12-month measurements of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol, platelets and white blood cells were obtained in the following four groups: tamoxifen (n = 1117), placebo (n = 1112), tamoxifen and HRT (n = 68), placebo and HRT (n = 87). The analysis was further extended to women who were on HRT at randomization but discontinued it during the 12-month intervention period (n = 33 on tamoxifen and n = 35 on placebo) and to women who were not on HRT but started it during intervention (n = 36 in both arms of the study). Compared with small changes in the placebo group, tamoxifen was associated with changes in total, LDL- and HDL-cholesterol of approximately -9{\%}, -19{\%} and +0.2{\%}, in continuous HRT users compared with -9{\%}, -14{\%} and -0.8{\%} in never HRT users. Similarly, there was no interaction on platelet count. In contrast, the decrease in total and LDL-cholesterol levels induced by tamoxifen was blunted by two-thirds in women who started HRT while on tamoxifen (P = 0.051 for the interaction term). We conclude that the beneficial effects of tamoxifen on cardiovascular risk factors are unchanged in current HRT users, whereas they may be attenuated in women who start transdermal HRT while on tamoxifen. Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity.",
keywords = "Breast neoplasm, Chemoprevention, Cholesterol, Oestrogen replacement therapy, Tamoxifen",
author = "A. Decensi and C. Robertson and N. Rotmensz and G. Severi and P. Maisonneuve and V. Sacchini and P. Boyle and A. Costa and U. Veronesi",
year = "1998",
month = "9",
language = "English",
volume = "78",
pages = "572--578",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial

AU - Decensi, A.

AU - Robertson, C.

AU - Rotmensz, N.

AU - Severi, G.

AU - Maisonneuve, P.

AU - Sacchini, V.

AU - Boyle, P.

AU - Costa, A.

AU - Veronesi, U.

PY - 1998/9

Y1 - 1998/9

N2 - The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks and side-effects of either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects of their combination on cardiovascular risk factors within a prevention trial of tamoxifen. Baseline and 12-month measurements of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol, platelets and white blood cells were obtained in the following four groups: tamoxifen (n = 1117), placebo (n = 1112), tamoxifen and HRT (n = 68), placebo and HRT (n = 87). The analysis was further extended to women who were on HRT at randomization but discontinued it during the 12-month intervention period (n = 33 on tamoxifen and n = 35 on placebo) and to women who were not on HRT but started it during intervention (n = 36 in both arms of the study). Compared with small changes in the placebo group, tamoxifen was associated with changes in total, LDL- and HDL-cholesterol of approximately -9%, -19% and +0.2%, in continuous HRT users compared with -9%, -14% and -0.8% in never HRT users. Similarly, there was no interaction on platelet count. In contrast, the decrease in total and LDL-cholesterol levels induced by tamoxifen was blunted by two-thirds in women who started HRT while on tamoxifen (P = 0.051 for the interaction term). We conclude that the beneficial effects of tamoxifen on cardiovascular risk factors are unchanged in current HRT users, whereas they may be attenuated in women who start transdermal HRT while on tamoxifen. Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity.

AB - The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks and side-effects of either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects of their combination on cardiovascular risk factors within a prevention trial of tamoxifen. Baseline and 12-month measurements of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol, platelets and white blood cells were obtained in the following four groups: tamoxifen (n = 1117), placebo (n = 1112), tamoxifen and HRT (n = 68), placebo and HRT (n = 87). The analysis was further extended to women who were on HRT at randomization but discontinued it during the 12-month intervention period (n = 33 on tamoxifen and n = 35 on placebo) and to women who were not on HRT but started it during intervention (n = 36 in both arms of the study). Compared with small changes in the placebo group, tamoxifen was associated with changes in total, LDL- and HDL-cholesterol of approximately -9%, -19% and +0.2%, in continuous HRT users compared with -9%, -14% and -0.8% in never HRT users. Similarly, there was no interaction on platelet count. In contrast, the decrease in total and LDL-cholesterol levels induced by tamoxifen was blunted by two-thirds in women who started HRT while on tamoxifen (P = 0.051 for the interaction term). We conclude that the beneficial effects of tamoxifen on cardiovascular risk factors are unchanged in current HRT users, whereas they may be attenuated in women who start transdermal HRT while on tamoxifen. Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity.

KW - Breast neoplasm

KW - Chemoprevention

KW - Cholesterol

KW - Oestrogen replacement therapy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0031903684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031903684&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 572

EP - 578

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -